45 results about "Systemic disease" patented technology

Disclosed herein are methods and devices for generating a trained generative foundation model for medical diagnosis, as well as using the trained generative foundation model for the detection of diseases and disorders including ophthalmic and systemic diseases. System and non-transitory computer-readable storage medium configured for performing the methods are also disclosed.

The invention discloses a method and system for screening drug targets with space-time specificity and computer equipment, and relates to the technical field of bioinformatics and computational biology. The screening method is based on single cell transcriptome sequencing data, and comprises the following steps: (1) quantitatively reconstructing spatial positioning and functional modes of cells in tissues, namely 1.1) carrying out data preprocessing on the single cell transcriptome sequencing data; 1.2) reconstructing the spatial positioning of the single cell; 1.3) reconstructing a single cell biological function mode; (2) screening a drug target with space-time specificity, wherein the screening comprises the following steps: 2.1) cell-cell communication analysis; the invention discloses a single-cell data analysis method based on a GRN (Gene Regulatory Network), which is characterized by comprising the following steps of (1) establishing a single-cell data analysis method, (2) establishing a GRN (Gene Regulatory Network) taking a specific tissue microenvironment state as a core, and (3) discovering a target spot. The single-cell data analysis method is innovative, provides a new thought and a technical path for research and development of drugs for metabolic diseases and other systemic diseases, and has a popularization and application basis.

In some embodiments provided herein is a generative foundation model trained over millions of health system-scale electronic health records along with web-scale medical text corpora to acquire knowledge of both medical practices and theories, and use of the generative model for rare disease diagnosis (including rare ophthalmic, diseases and rare systemic diseases), emergency condition identification (including ophthalmic emergencies and systemic emergencies), complex disease solving ("diagnostic puzzles"), or generating multimodal medical imaging reports (including ophthalmic images and radiology images such as X-rays and CT scans). In some embodiments, the generative model involves the use of language data, for pre-training, language data for supervised finetuning using a instruction tuning approach (e.g., QA pairs), and a human-machine hybrid evaluation strategy. In some embodiments, both the pre-training and supervised finetuning phases involve the use of a particular method of scaling to extend the context window. In some embodiments, the human-machine hybrid evaluation strategy involves language data for automated evaluations, as well as evaluations by generalists and by different specialists (e.g., ophthalmologists and radiologists) of varying levels of experience. In some embodiments, the generative foundation model, MetaGP, is used for unmet clinical needs through integration of medical and multimodal imaging data.

The invention discloses a magnetoelectric stent for realizing bone repair under external field driving and a preparation method and application thereof.The stent comprises a stent body based on a triple-period minimal curved surface structure and a magnetoelectric nano-particle coating, and the stent body comprises a convoluted and / or through hole structure; and the magnetoelectric nanoparticle coating is loaded on the inner surface of at least part of the pore structure. The magnetoelectric stent is suitable for providing better mechanical support for the early stage of bone repair of large-area bone defects, meanwhile, under the synergistic effect of magnetoelectric stimulation, osteogenesis and angiogenesis coupling can be promoted, and bone defect repair under the complex conditions of oral clinical alveolar bone vertical bone increment and systemic diseases such as inflammation and the like is achieved.

The invention discloses a garden disease and pest identification method and system based on computer image processing, and belongs to the technical field of disease and pest monitoring, and the method specifically comprises the steps: collecting a visible light image, an infrared image and environment parameters of vegetation; performing space-time registration on the visible light image and the infrared image and generating a three-dimensional temperature field model; the three-dimensional space is divided into grid units, and the temperature statistical characteristics and the vertical direction temperature gradient of each unit are extracted; obtaining an expected temperature gradient direction through a preset standard three-dimensional radiation field reference model; and when the actual gradient direction is consistent with the expected gradient direction, calculating a gradient direction deviation value of each grid unit, calibrating the grid unit with the deviation exceeding a threshold value as an abnormal region, and extracting a corresponding visible light image to carry out pest recognition. According to the invention, early-stage accurate identification of diseases and insect pests is realized, systematic diseases and local insect pests are effectively distinguished, interference of environmental factors is overcome, and the reliability of insect pest monitoring is improved.

The invention discloses a compound for preventing and treating related diseases caused by aldehyde metabolism disorder and application of the compound. The compound is a compound as shown in a formula (I) or a stereoisomer, a tautomer, a solvate and pharmaceutically acceptable salt of the compound as shown in the formula (I). The compound can be combined with active aldehyde to reduce the generation of an active aldehyde-biomacromolecule adduct and play a role in removing aldehyde, and can be used for treating various system diseases caused by aldehyde metabolism disorder. # imgabs0 #

The invention discloses a core-shell structure microneedle patch loaded with tetracycline antibacterial drugs and simvastatin as well as a preparation method and application of the core-shell structure microneedle patch, and belongs to the field of biomedical materials. An antibacterial drug doxycycline is loaded on a shell structure of a substrate layer and a needle body of the microneedle patch, and a core structure contains simvastatin-loaded polydopamine nanoparticles. The microneedle patch can release antibacterial drugs in stages, and the number of bacteria at local parts of a focus can be rapidly reduced in a short time through burst release of the antibacterial drugs in the first stage, so that inflammation spreading is controlled; in the second stage, the antibacterial medicine is slowly released, so that the formation of a new plaque biofilm is inhibited for a long time, meanwhile, simvastatin is slowly released, the effect of locally promoting osteogenesis is achieved, and the synergistic effect of antibiosis and bone regeneration is achieved. The compound has a good application prospect in the treatment of chronic periodontitis, especially intractable periodontitis combined with systemic diseases, such as chronic periodontitis combined with diabetes mellitus.

The current invention provides novel approaches to the treatment of various disease states that lead to altered cytokine release or cytokine storms. These diseases include viral infections immunological and other non-immunological diseases. Specifically, the invention provides methods targeting ZHX2 including methods of inhibition, blocking or depletion of ZHX2 in order to treat various disease states.

The present invention relates to novel dopamine D2 receptor ligands. The invention further relates to functionally-biased dopamine D2 receptor ligands and the use of these compounds for treating or preventing central nervous system and systemic disorders associated with dysregulation of dopaminergic activity.

The invention discloses a dynamic trajectory construction and visual mapping method for association of mental disorder brain network damage and systemic system diseases, and belongs to the field of artificial intelligence medical application. According to the method, high-resolution MRI images, biomarkers and clinical information of major mental disorder patients are collected, and the influence of factors such as age, gender, medication and diagnosis on the braingut axis and the cardio-cerebral axis is evaluated through multi-modal data fusion. By constructing a disease dynamic trajectory model, brain structures and function change modes corresponding to different mental disorders are identified. Large-scale samples are analyzed through machine learning, potential risks and protection factors are extracted, and a visual tool is developed to visually display changes of the brain under different disease systems. A closed-loop feedback mechanism is established through follow-up visit, the disease progress and the intervention effect are dynamically tracked, and key evaluation indexes are identified. According to the invention, theoretical basis and practical guidance are provided for early screening, precise intervention and personalized treatment of mental disorders, and the diagnosis and treatment accuracy and efficiency are remarkably improved.

The invention relates to an antibody or antigen binding fragment thereof which is capable of binding to CD1a. The antibody or antigen binding fragment thereof may be chimeric or humanised, and may be used to treat one or more inflammatory skin or mucosal disorder, or disease or one or more associated systemic disease or disorder, or one or more inflammatory drug reaction which manifests systemically, or a CD1a-expressing malignancy.

The invention belongs to the technical field of biological medicines, and particularly discloses application of inhibiting histone demethylase KDM4D in prevention and treatment of periodontitis. By constructing a mouse periodontitis and periodontitis animal model accompanied by systemic diseases, the influence of KDM4D intervention on periodontitis and periodontitis accompanied by systemic diseases is studied, and experimental results show that inhibition of KDM4D can down-regulate the expression level of osteoclast related genes, inhibit osteoclast differentiation, relieve alveolar bone resorption and bone loss, inhibit osteoclast differentiation and inhibit osteoclast differentiation. The traditional Chinese medicine composition has an obvious curative effect on periodontitis and periodontitis accompanied by systemic diseases, and a new prevention and treatment strategy is provided for periodontitis and periodontitis accompanied by systemic diseases.

The invention relates to CD1a-reactive T-cell receptors (TCRs), and their use in treating or preventing an inflammatory skin or mucosal disorder or disease or one or more associated systemic disease or disorder, one or more inflammatory drug reaction which manifests systemically, a CD1a-expressing malignancy or a malignancy wherein CD1a is altered in expression or function.

Disclosed herein are methods, devices and kits suitable for high throughput screenings of extracellular pyridine nucleotide levels, such as NAD+ levels which are suitable for monitoring pyridine nucleotide induced slowdown of not only pathogenesis of multiple systemic diseases but also aging. In particular, assaying methods quantifying extracellular pyridine nucleotide(s), such as NAD+, in the low micromolar to the low nanomolar range in a sample that may have been subjected to long term storage are disclosed using a two-step enzymatic cycling reaction employing an oxidoreductase such as alcohol dehydrogenase. A modified revised simulated body fluid is also disclosed that is employed as a standard matrix to optimise enzymatic activity, linearity and / or sensitivity of the methods, devices and kits.

The invention relates to a medicine for improving oral micro-ecology based on perilla leaves and application thereof, in particular to a medicine for improving oral micro-ecology based on perilla leaves and application thereof. The invention aims to solve the problem of human systemic diseases caused by oral harmful bacteria. The method comprises the following steps: crushing the perilla leaves, adding distilled water or ethanol with a volume concentration of 50% according to a mass ratio of the perilla leaves to the distilled water or ethanol with a volume concentration of 50% of 1: 20, soaking the distilled water in a closed container for 12 h, decocting for 3 h, and taking a filtrate; extracting with ethanol with the volume concentration of 50%, soaking in a closed container for 3 hours, performing ultrasonic extraction for 30 minutes, and taking filtrate; and repeatedly extracting the remaining medicines once, combining filtrates, concentrating the filtrates under reduced pressure, freeze-drying, preparing a solution with the medicine content of 1mg / mL by using distilled water, and sterilizing by using a 0.22 mu m filter membrane, thereby obtaining the traditional Chinese medicine composition. The medicine for improving the oral micro-ecology based on the perilla leaves is used for improving oral mucosa immune globulin. Through the perilla leaf extract, the secretion amount of immune globulin in oral mucosa is increased, and the oral microenvironment is improved.

A composition for treating peripheral neuropathy in a subject in need thereof. The composition comprises an effective amount of an agent selected from the group consisting of pirenzepine, oxybutynin, muscarinic toxin 7, muscarinic receptor antagonists, and combinations thereof, and a pharmaceutically acceptable carrier and / or excipient. The composition is used for treating peripheral neuropathy. Examples of the peripheral neuropathy are systemic disease-induced peripheral neuropathy, metabolic disease-induced peripheral neuropathy, chemotherapy-induced peripheral neuropathy, compression-induced peripheral neuropathy, dichloroacetate-contact-induced peripheral neuropathy, immune-mediated peripheral neuropathy, chemotherapy-induced peripheral neuropathy, chemotherapy-induced peripheral neuropathy, chemotherapy-induced peripheral neuropathy, chemotherapy-induced peripheral neuropathy, chemotherapy-induced peripheral neuropathy, chemotherapy-induced peripheral neuropathy, chemotherapy-induced peripheral neuropathy, chemotherapy-induced peripheral neuropathy and chemotherapy-induced peripheral neuropathy. And infection-induced peripheral neuropathy and gene-obtained peripheral neuropathy.

This invention provides an antibody fusion protein comprising a binding construct that targets and is capable of binding to Ang-2, IL-6 receptors, and at least one VEGF family member; or an antigen-binding fragment or domain of the antibody fusion protein. The antibody fusion protein comprises an antibody or binding peptide against Ang-2, an antibody against IL-6R, and multiple extracellular domains of the VEGF receptor as binding components. The antibody fusion protein is suitable for treating or controlling ocular or systemic diseases, symptoms, or conditions caused by abnormal angiogenesis, increased vascular leakage, or inflammation.

The invention relates to an antibody or antigen binding fragment thereof which is capable of binding to CD1a. The antibody or antigen binding fragment thereof may be chimeric or humanised, and may be used to treat one or more inflammatory skin or mucosal disorder, or disease or one or more associated systemic disease or disorder, or one or more inflammatory drug reaction which manifests systemically, or a CD1a-expressing malignancy.

The invention discloses a nutrition regulation and control method for disease resistance of kiwi fruits, a germination fertilizer and a preparation method, and the preparation method comprises the following steps: constructing a ternary interaction system consisting of a sulfur source, succinic acid and Pseudomonas fluorescens, and applying the ternary interaction system to rhizosphere nutrition management of the kiwi fruits in early spring. And three-dimensional coupling of nutrition supply, signal activation and microbial regulation and control is synchronously realized in the rhizosphere microdomain. Meanwhile, lignin monomer synthesis is continuously activated and promoted through a salicylic acid signal channel, high-activity laccase serves as a key enzyme for lignin monomer polymerization, lignin monomer polymerization reaction is accelerated, synthesis and deposition of lignin in plant cell walls are promoted, plant endogenous disease-resistant signal cascade is continuously amplified, and plant disease resistance is improved. The kiwi fruits are induced to generate stable systematic disease resistance. The composition can prevent and control diseases for a long time and cooperatively promote plant growth.

The present invention relates to an antibody or an antigen-binding fragment thereof capable of binding CD1a. The antibodies, or antigen-binding fragments thereof, may be chimeric or humanized, and may be used to treat one or more inflammatory dermatological or mucosal disorders or diseases, or one or more related systemic diseases or disorders, or one or more inflammatory drug responses of systemic manifestations, or CD1a-expressing malignancies.

The present application relates to the technical field of biological medicine, in particular to a Mongolian medicine composition with curative effect on liver disease based on data mining. National medicine has hundreds of years of clinical experience, can treat systemic diseases, and has definite curative effect. And its multi-component acts on multi-target, with small toxic and side effects. Through collating, summarizing and concluding the prescriptions recorded in Mongolian Medicine Prescriptions for treating liver disease, the use characteristics and compatibility rules of Mongolian medicine for treating liver disease are analyzed. The Mongolian medicine composition comprises safflower 180 parts, gardenia 60 parts, chebula 60 parts and five spirit resins 60 parts. The present application realizes efficient, systematic and low-toxic treatment of liver disease through the synergistic regulation mechanism of multi-component and multi-target, has obvious comprehensive advantages of liver protection, anti-inflammatory and anti-fibrosis and promotion of hepatocyte repair, fills the blank of multi-target traditional Chinese medicine combination scheme in the existing liver disease treatment field, and has important clinical popularization value and application prospect.

The invention discloses a nucleic acid construct, an amentoflavone production strain as well as a construction method and application of the amentoflavone production strain. The nucleic acid construct comprises nucleic acid for coding amentotaxus biflavone synthase and nucleic acid for coding a cytochrome P450 enzyme redox partner; the amentotaxus biflavone synthase has an amino acid sequence as shown in SEQ ID NO: 9. According to the invention, the amentotaxus biflavone production strain is established through a gene recombination technology, and biflavone fermentation production and manufacturing by using a heterologous artificial chassis are constructed for the first time. The prokaryotic production strain established by the invention is of great significance to development of novel drugs for treating neurodegenerative diseases and cardiovascular systemic diseases, and a new way is provided for industrial production of the potential drug amentotaxus biflavone.

The present invention refers to micro-fragmented fat or a composition comprising micro-fragmented fat for use in the treatment of a systemic disease, preferably associated to or caused by sepsis. Moreover, the micro-fragmented fat or the composition comprising micro-fragmented fat is used for treating a systemic, inflammatory, immune, or chronic disease, said disease being intended as a consequence of septic disease. Preferably, the micro-fragmented fat is useful for treating both the acute (early) and late stages of sepsis.

The present invention provides systems and methods for the detection of systemic disease from bacterial content samples obtained from a subject. Also provided are methods of training a machine learning algorithm to correlate patient microbiome sequence data with a disease state or disease development risk. These systems and methods utilize a high-resolution, database-independent, high-throughput microbial profiling platform to diagnose systemic disease in patients or to identify those patients at risk of developing systemic disease. Also provided are systems and kits for carrying out the methods.

The application discloses a kind of early warning method and device of children's eye disease and systemic genetic syndrome, it is related to ophthalmic examination equipment technical field.The method includes: collection ocular anterior segment image data set, utilize the multi-task segmentation model after training, obtain multiple congenital eye disease quantitative feature data, then based on the risk index calculator of pre-established index calculation is carried out, and the congenital eye disease risk index is obtained, classification processing is carried out, matches eye abnormal phenotype, and obtains systemic disease early warning report.The application can realize more than 10 kinds of congenital eye disease and rare but important lesion in one examination screening, and simultaneously establishes the intelligent early warning system of eye phenotype and systemic genetic syndrome.

The application discloses a screening method and system of a drug target with space-time specificity and a computer device, and relates to the technical field of bioinformatics and computational biology. The screening method is based on single-cell transcriptome sequencing data, and the method comprises the following steps: (1) quantitatively reconstructing the spatial positioning and functional mode of cells in a tissue, which comprises the following steps: 1.1) performing data preprocessing on the single-cell transcriptome sequencing data; 1.2) reconstructing the spatial positioning of single cells; and 1.3) reconstructing the biological functional mode of single cells; and (2) screening a drug target with space-time specificity, which comprises the following steps: 2.1) analyzing cell-cell communication; 2.2) constructing a gene regulatory network (GRN) with a specific tissue microenvironment state as the core; and 2.3) discovering a target. The application verifies an innovative single-cell data analysis method, and provides a new thought and technical path for drug research and development of metabolic diseases and other systemic diseases, and has the basis of popularization and application.

The present invention provides systems and methods for the detection of systemic disease from bacterial content samples, such as for example gut microbiome samples, obtained from a subject. Also provided are methods of training a machine learning algorithm to correlate patient microbiome sequence data with a disease state or disease development risk. These systems and methods utilize a high-resolution, database-independent, high-throughput microbial profiling platform to diagnose systemic disease in patients or to identify those patients at risk of developing systemic disease. Also provided are systems and kits for carrying out the methods.

The invention relates to a novel use of benzazepine, benzoxazepine, benzothiazepine-N-acetic acid and phosphono-substituted benzazepinone derivatives having both neutral endopeptidase (NEP) and / or human soluble endopeptidase (hSEP), and endothelin convertase (ECE), inhibitory activity. The compounds of this invention are useful for the preparation of pharmaceutical compositions to reduce harmful effects of symptomless progressive disseminated perfusion deficiency of organs, or parts thereof, that may be suggestive of systemic diseases.

A method and an apparatus for supporting a subject-customized prescription based on systemic disease risk are disclosed. An apparatus for providing subject-customized assistance information, according to one embodiment, comprises at least one processor, wherein the at least one processor: inputs medical data of a subject into a systemic disease-related risk prediction model so as to process the medical data; acquires, from the systemic disease-related risk prediction model, risk information about the subject as a processing result of the medical data; and provides the subject-customized assistance information on the basis of the risk information, the customized assistance information being generated using a risk change pattern analysis method for analyzing a change in the systemic disease risk over time on the basis of the risk information and / or a risk factor weight calculation method for calculating a weight of the risk information as one of a plurality of risk factors for cardiovascular disease.

A fusion protein comprises two VEGF-binding units, a least one of which comprises at least an extracellular domain of at least a VEGF receptor. The other VEGF-binding unit can comprise a VEGF-C antibody or at least a different extracellular domain of at least a VEGF receptor. The fusion protein can further comprise an Ang-2-binding unit. The fusion protein is useful in treating or controlling an ocular or systemic disease, condition, or disorder that has etiology in at least one of aberrant angiogenesis, increased vascular leakage, and inflammation.